1.Influence of the shoulder laxity on the shoulder lesion in several kinds of sports.
HIROKO NOMA ; YUKINORI TOMODA ; YOSHIHISA URITA ; TORU FUKUBAYASHI ; SHIGERU HARADA ; KENICHI TABUCHI
Japanese Journal of Physical Fitness and Sports Medicine 1986;35(2):93-103
The laxity of shoulder is one of main factors affecting shoulder lesions in athletes.
To measure the anterior-posterior laxity of shoulder, a stress machine was arranged because the ordinary rentogenographic measurement is not suitable. The measurement of the anterior-posterior laxity was done with athletes in several kinds of sports in which shoulder joints are mainly used. The result was compared with those from clinical examinations and stress rentogenography. Conclusions :
1. The anterior-posterior displacements of the affected side in baseball, volleyball and javelin players were significantly larger than that of the control side.
2. For the anterior-posterior displacement of the shoulder joint, baseball, volleyball and javelin players showed significantly larger values than truck runners as the control whereas significantly smaller values were found in water polo players.
3. There was no correlation between the anterior-posterior laxity and the inferior laxity.
2.Effect of Continuous Infusion of Midazolam on Refractory Headache and/or Nausea in Patients with Intracranial Cancer Lesions
Akiko HAGIWARA ; Aya MAKINO ; Hiroko HARADA ; Koji ODA ; Sigeko MATSUYAMA ; Tomoko KOMATSU ; Yumi SATO ; Shuichi KAMIYAMA ; Erika OKAMI ; Yukiko GODA
Palliative Care Research 2024;19(1):71-76
Objective: To investigate the effectiveness and safety of continuous infusion of midazolam for the treatment of headache and/or nausea/vomiting in patients with brain tumors or cancer-associated meningitis. Methods: Patients who presented with headache and/or nausea/vomiting and underwent continuous infusion of midazolam from April 2005 to March 2021 were retrospectively analyzed. Results: Among 22 patients, 19 presented with headache and 14 with nausea/vomiting. The success rate of continuous infusion of midazolam for headache was 89% and that for nausea/vomiting was 78%. The mean number of vomiting episodes within 24 hours from the start of midazolam administration was 0.14±0.36, which was significantly lower than that from 24 hours before to the start of administration (1.43±1.60, P=0.015). Sedation was observed as an adverse event in five (23%) patients, but no patients developed respiratory depression. Conclusion: When conventional therapies are ineffective for headache and/or nausea/vomiting caused by brain tumors or cancer-associated meningitis, continuous infusion of midazolam may improve symptoms and should be considered as a treatment option.